ATE388705T1 - Fentanyl zusammensetzung zur nasalen anwendung - Google Patents

Fentanyl zusammensetzung zur nasalen anwendung

Info

Publication number
ATE388705T1
ATE388705T1 AT01960190T AT01960190T ATE388705T1 AT E388705 T1 ATE388705 T1 AT E388705T1 AT 01960190 T AT01960190 T AT 01960190T AT 01960190 T AT01960190 T AT 01960190T AT E388705 T1 ATE388705 T1 AT E388705T1
Authority
AT
Austria
Prior art keywords
fentanyl
administration
nasal
results
action
Prior art date
Application number
AT01960190T
Other languages
German (de)
English (en)
Inventor
Jesper Grarup
Hanne Nielsen
Original Assignee
Nycomed Danmark Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE388705(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nycomed Danmark Aps filed Critical Nycomed Danmark Aps
Application granted granted Critical
Publication of ATE388705T1 publication Critical patent/ATE388705T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01960190T 2000-07-31 2001-07-31 Fentanyl zusammensetzung zur nasalen anwendung ATE388705T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200001154 2000-07-31

Publications (1)

Publication Number Publication Date
ATE388705T1 true ATE388705T1 (de) 2008-03-15

Family

ID=8159630

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01960190T ATE388705T1 (de) 2000-07-31 2001-07-31 Fentanyl zusammensetzung zur nasalen anwendung

Country Status (23)

Country Link
US (3) US8017627B2 (enExample)
EP (3) EP1642578B2 (enExample)
JP (2) JP4898073B2 (enExample)
KR (2) KR100888275B1 (enExample)
CN (2) CN100346788C (enExample)
AT (1) ATE388705T1 (enExample)
AU (2) AU8174601A (enExample)
CA (1) CA2417727C (enExample)
CY (2) CY1107405T1 (enExample)
DE (2) DE20122843U1 (enExample)
DK (2) DK1307194T4 (enExample)
EA (1) EA006384B1 (enExample)
EE (1) EE05420B1 (enExample)
ES (2) ES2427976T5 (enExample)
IL (2) IL154041A0 (enExample)
IS (1) IS2803B (enExample)
NO (2) NO330565B1 (enExample)
NZ (1) NZ524396A (enExample)
PL (1) PL207845B1 (enExample)
PT (2) PT1307194E (enExample)
SI (2) SI1642578T2 (enExample)
UA (2) UA77398C2 (enExample)
WO (1) WO2002009707A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
DE20122843U1 (de) 2000-07-31 2008-06-26 Nycomed Danmark Aps Fentanyl Zusammensetzung zur nasalen Anwendung
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
US20090281023A9 (en) * 2001-06-04 2009-11-12 Nobex Corporation Mixtures Of Calcitonin Drug-Oligomer Conjugates And Methods Of Use In Pain Treatment
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
GB0210264D0 (en) * 2002-05-03 2002-06-12 Arakis Ltd The treatment of pain and migraine headache
GB0300531D0 (en) * 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0305579D0 (en) * 2003-03-11 2003-04-16 Dallas Burston Ltd Pharmaceutical compositions
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20070053965A1 (en) * 2005-02-25 2007-03-08 Gruenenthal Gmbh Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
CN101472644B (zh) * 2006-04-13 2014-04-23 纽帕特公司 递送抗偏头痛化合物的透皮方法和系统
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
WO2009070829A1 (en) * 2007-12-05 2009-06-11 Krius Pty Ltd Non-aqueous oil-based fentanyl compositions for transmucosal administration
WO2009100383A2 (en) 2008-02-07 2009-08-13 University Of Washington Circumferential aerosol device
GB2464282A (en) * 2008-10-08 2010-04-14 Archimedes Dev Ltd A device for administering a dose of opioid analgesic
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
DE102009001041A1 (de) * 2009-02-20 2010-08-26 Marien-Apotheke Fulda Ohg Notfallset zur Herstellung eines Arzneimittels zur nasalen Anwendung von Opioiden bei Atemnot
EP2605816B1 (en) 2010-08-20 2019-01-23 University Of Washington Circumferential aerosol device for delivering drugs to olfactory epithelium and brain
SI2670674T1 (sl) 2011-02-04 2016-11-30 Archimedes Development Limited Izboljšan vsebnik
JP6339371B2 (ja) 2011-03-03 2018-06-06 インペル ニューロファーマ インコーポレイテッド 経鼻薬物送達デバイス
CN103619485B (zh) 2011-05-09 2017-08-08 英倍尔药业股份有限公司 用于鼻腔药物递送的喷嘴
DK2706982T4 (da) * 2011-05-13 2021-05-10 Euro Celtique Sa Intranasale farmaceutiske dosisformer omfattende naloxon
HK1222358A1 (zh) 2013-04-28 2017-06-30 Impel Neuropharma Inc. 医用单位剂量容器
NZ732808A (en) 2014-12-23 2021-12-24 Acelrx Pharmaceuticals Inc Systems, devices and methods for dispensing oral transmucosal dosage forms
CN108601916B (zh) 2015-09-10 2021-07-09 英倍尔药业股份有限公司 直列式鼻部递送装置
WO2019104192A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with inlet interface
JP7191099B2 (ja) 2017-11-21 2022-12-16 インペル ファーマシューティカルズ インコーポレイテッド 浸漬管を備えた鼻腔内装置
AU2019205329B2 (en) 2018-01-05 2023-04-20 Impel Pharmaceuticals Inc. Intranasal delivery of olanzapine by precision olfactory device
RU2020125871A (ru) 2018-01-05 2022-02-07 Импел Ньюрофарма, Инк. Интраназальная доставка дигидроэрготамина с помощью прецизионного устройства для доставки в обонятельную область
EP3823607A4 (en) 2018-07-19 2022-04-06 Impel NeuroPharma Inc. ADMINISTRATION OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR INTO THE RESPIRATORY TRACT FOR THE TREATMENT OF PARKINSON'S DISEASE
SG11202107019VA (en) 2019-01-03 2021-07-29 Impel Neuropharma Inc Nasal drug delivery device
WO2020236658A1 (en) 2019-05-17 2020-11-26 Impel Neuropharma, Inc. Single-use nasal delivery device
US20230372327A1 (en) 2020-10-15 2023-11-23 Pharmbiotest Poland Sp. z o. o. Pharmaceutical composition based on nalbuphine and/or its salts for nasal administration

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4486423A (en) * 1983-04-21 1984-12-04 Janssen Pharmaceutica Inc. Stable fentanyl composition
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
FR2568773B1 (fr) 1984-08-10 1989-03-03 Sandoz Lab Nouvelles compositions pharmaceutiques administrables par voie nasale
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5122127A (en) * 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
ZA875317B (en) 1986-08-01 1988-01-25 Warner-Lambert Company Transdermal compositions
US4916142A (en) 1987-02-02 1990-04-10 Boc, Inc. N-heterocyclic-N-(4-piperidinyl)amides and pharmaceutical compositions and their use as analgesics
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
US5019583A (en) 1989-02-15 1991-05-28 Glaxo Inc. N-phenyl-N-(4-piperidinyl)amides useful as analgesics
US5098915A (en) 1989-09-05 1992-03-24 G. D. Searle & Co. Substituted N-benzylpiperidine amides
US5028616A (en) 1989-09-05 1991-07-02 G. D. Searle & Co. N-benzylpiperidine amides
ATE164080T1 (de) 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
AU5551394A (en) 1992-11-09 1994-06-08 Pharmetrix Corporation Combined analgesic delivery methods for pain management
US5507277A (en) * 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
US5466700A (en) 1993-08-30 1995-11-14 Glaxo Wellcome Inc. Anesthetic use of N-phenyl-N-(4-piperidinyl)amides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
USRE38407E1 (en) 1994-03-23 2004-01-27 Delex Therapeutics Inc. Pain management with liposome-encapsulated analgesic drugs
EP0759744B1 (en) * 1994-05-13 2001-10-17 Aradigm Corporation Narcotic containing aerosol formulation
PT704206E (pt) 1994-09-30 2003-01-31 Mika Pharma G Fur Die E Und V Composicao farmaceutica
BR9609358A (pt) 1995-06-05 1999-05-18 Alza Corp Dispositivo para distribuição transdérmica por eletrotransporte fentanil e sufentanil
IE960375A1 (en) 1995-06-05 1996-12-11 Alza Corp Device for transdermal electrotransport delivery of fentanyl¹and sufentanil
US6881208B1 (en) 1995-06-05 2005-04-19 Joseph B. Phipps Method and device for transdermal electrotransport delivery of fentanyl and sufentanil
DE69637920D1 (de) * 1995-06-07 2009-06-18 Oneil Alexander G B Vom Patienten gesteuerte Vorrichtung zur Arzneimittelabgabe
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6787149B1 (en) 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US6143278A (en) 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
GB9823246D0 (en) 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
US6660715B2 (en) 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
US7074388B2 (en) 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
AU2879100A (en) * 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
US6680071B1 (en) 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6677332B1 (en) 1999-05-25 2004-01-13 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
ATE463259T1 (de) 1999-08-26 2010-04-15 Takeda Pharmaceutical Nasenschleimhaut haftende matrix
US7074803B2 (en) 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
WO2002011778A1 (en) 2000-05-10 2002-02-14 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US20040115133A1 (en) 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US7049326B2 (en) 2000-05-12 2006-05-23 The University Of Toledo Method and compositions for temporarily incapacitating subjects
AU2001216218A1 (en) 2000-05-25 2001-12-11 Sepracor, Inc. Heterocyclic analgesic compounds and method of use thereof
AU2001274307A1 (en) 2000-06-22 2002-01-02 Pharmasol Ltd Pharmaceutical compositions
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
DE20122843U1 (de) 2000-07-31 2008-06-26 Nycomed Danmark Aps Fentanyl Zusammensetzung zur nasalen Anwendung
US20020106407A1 (en) 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
JP4850346B2 (ja) 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
US20020187996A1 (en) 2001-05-14 2002-12-12 Dewey Stephen L. Prevention of addiction in pain management
FR2829757B1 (fr) * 2001-09-20 2004-07-09 Commissariat Energie Atomique Procede de preparation d'un sol stable de zircono-titanate de plomb et procede de preparation de films a partir dudit sol
AU2003281182A1 (en) 2002-07-11 2004-02-02 Taiho Pharmaceutical Co., Ltd. Composition for nasal absorption
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
US20040102476A1 (en) 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20060062812A1 (en) 2003-03-11 2006-03-23 Calvin Ross Novel compositions
AP2005003467A0 (en) 2003-06-17 2006-12-31 Pfizer N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline reuptake inhibitors.
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
GB0514043D0 (en) 2005-07-08 2005-08-17 Arakis Ltd Fentanyl formulation
PT1976521E (pt) 2006-01-25 2015-06-09 Insys Therapeutics Inc Aerossol sublingual de fentanilo
WO2009047779A2 (en) 2007-06-20 2009-04-16 Nikki Nikhilesh Singh Composition containing fentanyl base aromatic oils and alkyl salicylate for the delivery of fentanyl base in vapour form
ES2668366T3 (es) 2007-08-02 2018-05-17 Insys Development Company, Inc. Pulverización sublingual de fentanilo
WO2009070829A1 (en) 2007-12-05 2009-06-11 Krius Pty Ltd Non-aqueous oil-based fentanyl compositions for transmucosal administration

Also Published As

Publication number Publication date
PL365053A1 (en) 2004-12-27
JP2008044951A (ja) 2008-02-28
IL154041A (en) 2011-05-31
AU2001281746B2 (en) 2006-10-05
EE200300050A (et) 2004-12-15
IL154041A0 (en) 2003-07-31
DE20122843U1 (de) 2008-06-26
US8158651B2 (en) 2012-04-17
EP2255806A2 (en) 2010-12-01
SI1307194T2 (sl) 2011-07-29
SI1642578T1 (sl) 2013-10-30
AU8174601A (en) 2002-02-13
PT1307194E (pt) 2008-05-27
DE60133203T3 (de) 2012-02-23
JP4898073B2 (ja) 2012-03-14
CY1114645T1 (el) 2016-10-05
PL207845B1 (pl) 2011-02-28
EP1642578B1 (en) 2013-07-03
CN1466455A (zh) 2004-01-07
KR20080053423A (ko) 2008-06-12
NO20030365D0 (no) 2003-01-24
KR20030034126A (ko) 2003-05-01
DE60133203T2 (de) 2009-04-30
DK1307194T4 (da) 2011-07-18
UA77398C2 (en) 2006-12-15
EP1307194B2 (en) 2011-04-27
NZ524396A (en) 2003-09-26
KR100888275B1 (ko) 2009-03-10
US20110281914A1 (en) 2011-11-17
DE60133203D1 (de) 2008-04-24
DK1307194T3 (da) 2008-07-14
AU2001281746C1 (en) 2010-09-09
SI1307194T1 (sl) 2008-08-31
NO20110342L (no) 2003-03-31
EA006384B1 (ru) 2005-12-29
NO333809B1 (no) 2013-09-23
CY1107405T1 (el) 2012-12-19
HK1089106A1 (en) 2006-11-24
EA200300201A1 (ru) 2003-06-26
US8017627B2 (en) 2011-09-13
NO330565B1 (no) 2011-05-16
CN101181241A (zh) 2008-05-21
ES2302742T5 (es) 2011-10-10
ES2302742T3 (es) 2008-08-01
IS6702A (is) 2003-01-28
WO2002009707A1 (en) 2002-02-07
US20070134164A1 (en) 2007-06-14
US20040034059A1 (en) 2004-02-19
EP1307194A1 (en) 2003-05-07
DK1642578T3 (da) 2013-08-12
CA2417727C (en) 2009-09-01
CN100346788C (zh) 2007-11-07
NO20030365L (no) 2003-03-31
ES2427976T5 (es) 2022-04-13
IS2803B (is) 2012-09-15
SI1642578T2 (sl) 2022-01-31
JP2004505052A (ja) 2004-02-19
EP1642578A3 (en) 2006-09-27
ES2427976T3 (es) 2013-11-05
UA89755C2 (ru) 2010-03-10
EP1307194B1 (en) 2008-03-12
EP1642578A2 (en) 2006-04-05
EE05420B1 (et) 2011-06-15
EP1642578B2 (en) 2021-11-03
US8653107B2 (en) 2014-02-18
EP2255806A3 (en) 2011-06-29
CA2417727A1 (en) 2002-02-07
PT1642578E (pt) 2013-09-30

Similar Documents

Publication Publication Date Title
ATE388705T1 (de) Fentanyl zusammensetzung zur nasalen anwendung
DK1458388T3 (da) En flydende farmaceutisk formulering omfattende nikotin til administrering i mundhulen
DE60202477D1 (de) Vorrichtung zur verabreichung einer substanz
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
NO20032111L (no) Nye medikamentblandinger basert pa tiotropium-salter og pa salmeterol-salter
DE60322102D1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
NZ594154A (en) Transdermal administration of buprenorphine for preoperative treatment of post operative pain
ATE473001T1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
ATE452639T1 (de) Arzneimittelkompositionen aus tiotropiumsalzen und epinastin zur therapie von atemswegserkrankungen
TW200514582A (en) Transdermal preparation and method for reducing side effect in pergolide therapy
AU8900498A (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
UY27037A1 (es) Composición de apomorfina para tratar la disfunción sexual con niveles específicos de concentración en plasma

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1307194

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1307194

Country of ref document: EP